Anti-Müllerian hormone dynamics during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome by Dąbkowska-Huć, Anna et al.
203
Prace oryginalne/original PaPers
Endokrynologia Polska
Tom/Volume 64; Numer/Number 3/2013
ISSN 0423–104X
Anna Dąbkowska-Huć M.D., Ph.D. Gynecological Endocrinology Department, Medical University of Silesia, Medyków D St.14,  
40–752 Katowice; tel. 32 789 43 61, tel./fax 32 789 43 51, e-mail: ahuc1@wp.pl
Anti-Müllerian hormone dynamics during ovulation 
induction treatment with recombinant follicle-stimulating 
hormone in women with polycystic ovary syndrome
Hormon anty-Müllerowski (AMH) jako marker folikulogenezy w jajnikach kobiet 
z zespołem policystycznych jajników
Anna Dąbkowska-Huć, Magdalena Lemm, Jerzy Sikora, Andrzej Witek, Piotr Skałba
Gynaecological Endocrinology Department, Medical University of Silesia, Katowice, Poland
Abstract
Introduction: Anti-Müllerian hormone (AMH) has been suggested as a predictor of ovarian response to ovulation induction and controlled 
ovarian hyperstimulation.
Patients and methods: Twenty-six women, wishing to become pregnant and who showed resistance to clomiphene citrate, were included 
in the study. All women received recombinant follicle-stimulating hormone (recFSH). 
Results: In the group of good responders, luteinising hormone (LH) and oestradiol levels were lower than in the group of non-responders. 
Free testosterone levels, free androgen index, and insulin resistance were higher in the group of non-responders. In the group of good 
responders, AMH levels decreased on successive days of ovarian stimulation and a greater slope of AMH levels was observed in patients 
with a higher number of increasing follicles.
PCOS patients have low FSH and high AMH levels. It could be suggested that the serum AMH decrease preceded growth of many fol-
licles, which is a consequence of the FSH stimulation. In anovulatory PCOS women, gently increasing the serum FSH level reduces the 
AMH excess, thus relieving the inhibition from the latter on aromatase expression by selectable follicles and allowing the emergence of 
growing follicles. Patients with severe hyperandrogenism, insulin resistance and high level of LH do not respond to stimulation. 
Conclusions: The decrease of AMH levels in PCOS women after one week of ovarian stimulation is a practical, valuable indicator which 
could predict the patients with a high risk of ovarian hyperstimulation. Anovulating PCOS patients with severe hyperandrogenism, insulin 
resistance and hyperinsulinaemia should not be qualified for recFSH ovarian stimulation. (Endokrynol Pol 2013; 64 (3): 203–207)
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Streszczenie
Wstęp: Hormon anty-Müllerowski (AMH) jest uznawany za marker odpowiedzi jajników na stymulację owulacji. 
Materiał i metody: Do badania włączono 26 kobiet pragnących zajść w ciążę i wykazujących oporność na leczenie cytrynianem klomifenu. 
Wszystkie pacjentki były stymulowane rekombinowaną folitropiną. 
Wyniki: W grupie dobrze odpowiadającej na stymulację stężenia lutropiny i estradiolu były niższe niż w grupie nieodpowiadającej. Stężenie wolnego 
testosteronu, indeks wolnych androgenów i insulinooporność były większe w grupie nieodpowiadającej na stymulację. W grupie odpowiadającej 
stężenie AMH obniżyło się w kolejnych dniach stymulacji i spadek ten był wyraźniejszy u pacjentek z większą liczbą wzrastających pęcherzyków. 
Pacjentki z PCOS wykazują niskie stężenia FSH i wysokie AMH. Uważa się, że obniżenie stężenia AMH poprzedza wzrost pęcherzyków 
w trakcie stymulacji rekombinowanym FSH. U bezowulacyjnych pacjentek z PCOS łagodny wzrost w surowicy FSH hamuje AMH, 
odblokowując ekspresję aromatazy przez wybrane pęcherzyki, co pozwala na wyłonienie rosnących pęcherzyków. Kobiety z nasilonym 
hiperandrogenizmem, insulinoopornością i wysokim poziomem LH nie odpowiadają na stymulację. 
Wnioski: Obniżenie stężenia AMH u pacjentek z PCOS po tygodniu stymulacji rekombinowanym FSH jest praktycznym, cennym 
markerem pozwalającym wyłonić pacjentki z wysokim ryzykiem zespołu hiperstymulacji. Bezowulacyjne pacjentki z PCOS z ciężkim 
hiperandrogenizmem, insulinoopornością i hiperinsulinemią nie powinny być kwalifikowane do stymulacji owulacji rekombinowanym 
FSH. (Endokrynol Pol 2013; 64 (3): 203–207)
Słowa kluczowe: hormon anty-Mullerowski, stymulacja owulacji, zespół policystycznych jajników
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Introduction
Follicle-stimulating hormone (FSH) is an appropri-
ate first-line treatment for women with polycystic 
ovary syndrome and anovulatory infertility [1]. Anti-
Müllerian hormone (AMH) has been suggested as a 
predictor of ovarian response to ovulation induction 
and controlled ovarian hyperstimulation. In human 
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ovaries, AMH is produced by granulosa cells, with the 
highest expression being in small antral follicles, and 
continues to be expressed in the growing follicles until 
they have reached the size and differentiation state at 
which they are to be selected for dominance [2].
Many recently published studies have confirmed 
elevated concentrations of AMH in the blood of women 
with polycystic ovary syndrome (PCOS) [3–5]. As is well 
known, PCOS is characterised by an increase in follicle 
number of small antral follicles. AMH controls follicu-
logenesis by reducing follicle sensitivity to FSH, and 
leads to anovulation when secreted in excess amounts 
in polycystic ovary syndrome. It has been proved, how-
ever, that follicle number only added 5.3% to variance 
in the concentration of AMH, and raised production 
of hormone is an intrinsic property of granulosa cells 
in PCOS [4,6,7]. Although the cause of increased AMH 
production in PCOS remain unclear, this fact is impor-
tant in explaining the mechanism of folliculogenesis 
disorders in this syndrome, and also for the effective 
stimulation of ovulation. 
Serum AMH levels in young normo-ovulatory 
women correlate not only with age and the number of 
antral follicles, but also with FSH levels. Durlinger et al. 
proved in an in vitro study that AMH hormone inhibits 
antral follicle responsiveness to FSH [8]. Exogenous FSH 
administration is followed by a significant reduction in 
AMH levels. Several studies have demonstrated AMH 
secretion changes during controlled ovarian hyper-
stimulation (COH). The changes consist of a progressive 
reduction of serum hormone levels, which correlate with 
the dose of gonadotrophins used [5, 9, 10]. Therefore, 
the serum AMH levels during COH are good markers to 
predict ovarian response. Moreover, AMH may permit 
identification of the extremes of ovarian stimulation. 
A possible role for its measurement may be in individualisa-
tion of treatment strategies in PCOS anovulatory women.
The question then arises: what is the practical value 
of AMH determinations in patients with PCOS, treated 
with the recFSH stimulation? The answer to this ques-
tion is the main objective of this study.
Material and methods
Twenty-six women attending the Gynaecological En-
docrinology Department between January 2011 and 
March 2012 were included in the study. All patients 
gave signed informed consent. Procedures followed 
were in accordance with ethical standards and the study 
received approval from the Silesian Medical University 
Ethics Committee.
The diagnosis of PCOS was made on the basis of 
chronic oligomenorrhea, and either clinical hyperan-
drogenism (hirsutism — Ferriman-Gallwey score > 8) 
or hyperandrogenemia (high free testosterone or high 
free androgen index > 8%). All of the women studied 
showed typical features of polycystic ovaries detected 
by ultrasound, considered to be one of the criteria for 
diagnosis of this syndrome. Other entities that could 
cause excess androgen activity were excluded. Thus, 
patients included in the study met both the Rotterdam 
diagnostic criteria of PCOS, and also the Androgen Ex-
cess PCOS Society diagnostic criteria of this syndrome.
Women included in the study were aged 24–35 
years, wishing to become pregnant, and showed re-
sistance to clomiphene citrate. Previously performed 
examinations have established that these women are 
characterised by a chronic anovulation (ultrasound 
evaluation of ovarian follicular maturation and serum 
levels of oestradiol and progesterone determinations). 
All patients before treatment underwent measurement 
of plasma levels of oestradiol, total and free testoster-
one, sex hormone binding globulin (SHBG), luteinising 
hormone (LH), FSH, thyroid stimulating hormone 
(TSH), prolactin, 17-hydroxyprogesterone (17OHP), 
and AMH, as well as vaginal ultrasound.
All women were investigated during only one cycle and 
received recombinant FSH (recFSH) (Puregon; Organon Nl) 
using the low-dose protocol. Patients received 50 IU recFSH 
daily for the first seven days. If ovarian stimulation had been 
ineffective and follicles had not reached the diameter of 
10 mm, the dose of recFSH was increased to 100IU for the 
next seven days. Treatment was started on day 3 after onset 
of either spontaneous or progesterone-(Luteine; Adamed 
Pl) induced menstruation. During treatment, patients were 
hospitalised. Treatment was monitored by daily transvagi-
nal ultrasound examination. The ultrasound examination 
(Voluson 730 Expert) was performed with special regard to 
number and diameter of ovarian follicles.
The end-point of the study was achieved by one 
or more follicles being more than 17 mm in diameter. 
When the follicle reached a sufficient diameter before 
14 days of treatment, it was interrupted. If the follicles 
did not grow within 14 days of treatment, the study 
was stopped. After evaluation, women were divided 
into two groups:
Patients who responded to stimulation with recFSH 
— the dominant follicle 17 mm or more (20 patients — 
we called this group the good responders)
Patients who did not respond to stimulation with 
recFSH (six patients — non-responders).
Blood samples for the determination of AMH were 
taken three times: before treatment, on the last day of 
stimulation, and afterwards. 
The collected blood was centrifuged and sera were 
stored at –70°C until analysed (no longer than 30 days). 
Blood serum concentrations of AMH were determined 
using ELISA (DRG Instruments GmbH, Germany). The 
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assays were performed according to the manufacturer’s 
instruction.
Results
In the group of good responders, LH and oestradiol 
levels were lower than in the group of non-responders 
(LH: 8.505 ± 4.971 v. 11.683 ± 2.491, p < 0.05; oestradiol: 
44.780 ± 14.168 v. 57.18 ± 6.4, p < 0.05). There was no 
difference in the levels of FSH, prolactin and AMH 
between the group of good responders and the group 
of non-responders (Table I). 
Free testosterone levels and FAI were higher in pa-
tients who did not respond to stimulation of ovulation 
(free testosterone: 5.02 ± 1.6 v. 2.912 ± 1.7; FAI: 9.2 ± 
± 5.4 v. 4.8 ± 3.9, p < 0.05) (Table I).
Insulin fasting levels and the Homeostasis Model 
Assessment (HOMA) were higher in the group of non-
responders than patients who responded to recFSH 
(insulin: 11.05 ± 1.8 v. 9.01 ± 4.1, p < 0.05; HOMA: 2.64 ± 
± 0.49 v. 2.1 ± 1.07, p < 0.05) (Table I).
In all patients who responded to recFSH, AMH lev-
els decreased on successive days of ovarian stimulation 
(p < 0.05). (Fig. 1). In patients with a higher number 
of dominant follicles, the decrease of AMH followed 
earlier and the stimulation was interrupted after one 
week. In the non-responders, AMH results were similar 
on all days of evaluation. 
Moreover, we observed a greater slope of AMH lev-
els in patients with higher number of increasing follicles 
(diameter > 17 mm) in the group of good responders 
(p < 0.05) (Table II).The slope of AMH levels was greater 
in patients with higher levels of LH in the group of good 
responders (Table II). 
Discussion
AMH is generally considered as a regulator of the 
early stages of follicular development [10]. AMH 
induces reduction in the response of the growing 
follicles to FSH. Thus, FSH-stimulated preantral fol-
licular growth in vitro is suppressed in the presence of 
AMH ([10]. La Marca et al. [10] proved that in normal 
menstruating infertile women, recFSH treatment 
decreases AMH levels. Moreover, the authors found 
a correlation between decrease of AMH and increase 
of oestradiol, and a positive correlation between basic 
level of AMH and the level of oestradiol after recFSH 
treatment in normal women. In PCOS patients, the 
observations are different. PCOS patients have low 
FSH and high AMH levels. In these patients, there 
is a relationship between AMH levels and menstrual 
disorders and also between AMH levels and the 
antral follicle count (AFC) [11–13]. The treatment of 
anovulating PCOS patients is difficult especially in 
those who are resistant to clomiphene stimulation. 
Table I. Difference in hormonal evaluation between group of good responders and group of non-responders before stimulation
Tabela I. Różnice stężeń hormonów między pacjentkami dobrze odpowiadającymi i nieodpowiadającymi na stymulację przed 
rozpoczęciem stymulacji
Result Medium level in group of 
good responders
Medium level in group of 
non-responders
Difference between 
groups of good responders 
and non-responders
p
AMH [ng/mL] 7.72 6.62 1.1 0.78974
FSH [mIU/mL] 5.56 6.67 –1.11 0.17559
LH [mIU/mL] 8.50 11.68 –3.18 0.01314
Oestradiol [pg/mL] 44.78 57.18 –12.4 0.03907
Prolactin [ng/mL] 22.04 22.88 –0.84 0.69994
Free testosterone [ng/mL] 2.91 5.02 –2.11 0.01939
Insulin [mIU/mL] 9.01 11.05 –2.04 0.01314
HOMA 2.13 2.64 –0.51 0.04586
Table II. AMH levels in the group of good responders (group 1) and the group of non-responders
Tabela II. Stężenie AMH w grupie dobrze odpowiadającej i nieodpowiadającej na stymulację
AMH day 1 AMH day 7 Difference between 
day 1 and 7 (p)
AMH day 14 Difference between 
day 1 and 14 (p)
Difference between 
day 7 and 14 (p)
Group 1 7.725 6.025 0.00197 4.314 0.00056 0.00197
Group 2 6.617 6.833 p > 0.5 6.377 p > 0.5 p > 0.5
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PCOS patients are in the group of high risk of hyper-
stimulation. It has been shown that in vitro FSH sig-
nificantly reduced AMH expression in cultured GCs 
from PCOS patients [14]. From these results, it could 
be suggested that the serum AMH decrease preceded 
the follicle dominance, which is a consequence of the 
FSH stimulation [5]. La Marca et al. [10] examined 
AMH levels during ovarian stimulation in healthy 
anovulatory patients. During FSH administration, FSH 
and oestradiol levels increased and the levels were 
significantly higher than in the spontaneous cycle [10]. 
AMH levels decreased progressively from day 2 to day 
6 in FSH-treated cycles but did not change in spontane-
ous cycles [10]. A significant slope of AMH levels was 
observed in our patients with PCOS who responded 
to recFSH stimulation. In patients with several grow-
ing follicles, the decrease of AMH followed earlier and 
was more significant. Catteau-Jonard et al. [5] obtained 
similar results in PCOS patients. They suggested that 
in anovulatory PCOS women, gently increasing the 
serum FSH level reduces the AMH excess, thus relieving 
the inhibition from the latter on aromatase expression 
by selectable follicles and allowing the emergence of 
a dominant follicle [5]. 
Our results confirmed that PCOS patients treated 
with recFSH could be divided into two groups. The 
patients with lower levels of LH, FAI and HOMA 
respond to recFSH stimulation. Patients with severe 
hyperandrogenism, insulin resistance and high level 
of LH on the third day of the cycle do not respond to 
stimulation. Moreover, the slope of AMH levels was 
higher in patients who develop a dominant follicle 
after stimulation. 
There is a significant difference in the levels of LH, 
oestradiol, free testosterone, insulin and HOMA be-
tween the two groups of patients. However, there are 
no differences in the levels of AMH, FSH and prolactin 
on the second day of the cycles. We suggest that basic 
levels of the above parameters are not good markers 
to predict the success of ovarian stimulation. Similar 
results were obtained by Lie Fong et al. [15]. But these 
authors also suggested that there is a lack of change in 
AMH concentrations during low-dose ovarian stimula-
tion contrary to controlled ovarian hyperstimulation. 
In our results, there was a decrease of AMH level in 
patients with many growing follicles after seven days 
of ovarian stimulation, contrary to stable levels of AMH 
in patients who did not respond to recFSH stimulation. 
Biasoni et al. [16] analysed AMH and ovarian sensitivity 
index (OSI), which was calculated dividing the total 
administered FSH dose by the number of retrieved 
oocytes. They found a significant negative correla-
tion between AMH and OSI that is stronger than the 
one between AMH and the total number of retrieved 
oocytes. In our investigation, it was interesting that 
non-responders had significantly higher levels of LH, 
free testosterone, FAI and HOMA. This indicates that in 
patients with severe PCOS there is decreased response 
to recFSH. We suggest that these patients may require 
higher doses. We may conclude that severity of PCOS, 
which is connected with a greater number of small fol-
licles and a high level of AMH, requires higher doses 
of recFSH. 
Conclusions
A decrease in AMH levels in PCOS women after one 
week of ovarian stimulation is a practical, valuable 
indicator which could predict the patients with a high 
risk of ovarian hyperstimulation. Anovulating PCOS 
patients with severe hyperandrogenism, insulin resist-
ance and hyperinsulinemia should not be qualified for 
recFSH ovarian stimulation. 
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